Yıl: 2021 Cilt: 19 Sayı: 1 Sayfa Aralığı: 95 - 101 Metin Dili: İngilizce DOI: 10.4274/tybd.galenos.2021.30316 İndeks Tarihi: 13-06-2022

Pneumothorax and Subcutaneous Emphysema Evaluation in Patients with COVID-19 in the Intensive Care Unit

Öz:
Objective: Pneumothorax (PNX) and subcutaneous emphysema (SCE) have increased in importance as a frequently occurring complication. This study aimed to reveal the frequency, timing, and possible risk factors in patients with PNX and SCE who are followed up with coronavirus disease-2019 (COVID-19) diagnosis in our tertiary intensive care unit (ICU). Materials and Methods: All patients with confirmed COVID-19 who were followed up and treated in our unit between August 8, 2020, and February 20, 2021, in a 16-bed tertiary ICU and who developed PNX and SCE during their hospitalization were included. Results: PNX and SCE developed in 16 (9.6%) of 165 patients who were followed up in our ICU due to COVID-19. Of these 16 patients, 3 (18.8%) survived. The median age of patients was 66.5 years (interquartile range: 58.5-75.5). Diabetes mellitus was the most common comorbidity in patients with PNX and SCE. Additionally, 12 (75%) patients had a smoking history. Of 15 (93.8%) patients who developed PNX, 4 (25%) were bilateral, and SCE developed in 9 (56.3%) patients. Twelve (75%) patients with PNX and SCE were under invasive mechanical ventilation, 3 (18.8%) under spontaneous breathing, and 1 (6.2%) under non-invasive mechanical ventilation treatment. The number of oxygen support days until the time PNX and SCE developed was 9 (6.25-17) days in the whole group, the median time was 6 days in the survival group and 9 days in the non-survival group. Conclusion: In the COVID-19 pandemic, complications, such as PNX and SCE, are more frequently observed (9.5%) than in the general intensive care population and the later period of intensive care admission (median 9 days). Smoking is defined as a risk factor in most of these patients; however, increased PNX rates are thought to be related to both COVID-19 pneumonia and parenchymal damage due to cytokine storms
Anahtar Kelime:

COVID-19 Tanılı Yoğun Bakım Hastalarında Pnömotoraks ve Subkütan Amfizem Olgularının Değerlendirilmesi

Öz:
Amaç: Koronavirüs hastalığı-2019 (COVID-19) ile takipli yoğun bakım hastalarında pnömotoraks (PNX)/deri altı amfizem (SCE) pandeminin ilk zamanlarında yapılan tanımlamaların aksine sık ortaya çıkan bir komplikasyon olarak önemini artırmaktadır. Bu çalışma ile 3. düzey yoğun bakım ünitemizde (YBÜ) COVID-19 tanısı ile takip edilen PNX/SCE olgularının sıklığını, zamanlamasını ve olası risk faktörlerini ortaya koymak hedeflenmiştir. Gereç ve Yöntem: On altı yataklı 3. düzey YBÜ’de, 28 Ağustos 2020 ve 20 Şubat 2021 arasında ünitemizde takip ve tedavi edilmiş tüm teyitli COVID-19 hastalarından, yatışları sırasında PNX ve SCE gelişen olgular dahil edilmiştir. Bulgular: Hedef tarih aralığında YBÜ’de COVID-19 nedeni ile 165 hasta takip edilmiş olup bu hastaların 16’sında (%9,6) PNX/SCE gelişmiştir. Bu 16 hastanın 4’ü (%25) sağ kalmıştır. Hastaların medyan yaşı 66,5 (çeyrekler açıklığı: 58,5-75,5) idi. PNX/SCE gelişen hastalarda en sık komorbidite diabetes mellitus olarak tespit edildi. Hastaların 12’sinin (%75) sigara kullanım öyküsü mevcuttu. PNX gelişen 15 (%93,8) hastanın 4’ü (%25) bilateraldi. SCE ise 9 (%56,3) hastada gelişti. PNX/ SCE saptanan 12 (%75) hasta invazif mekanik ventilasyon tedavisi altındayken, 3 (%18,8) hasta spontan solunumda, 1 (%6,2) hasta non-invazif mekanik ventilasyon tedavisi altındaydı. PNX/SCE geliştiği ana kadar oksijen desteği verilen gün sayısı tüm grupta 9 (6,25-17) gün iken, sağkalan grupta medyan değer 6 gün, ölen grupta 9 gün idi. Oksijen destek gün süresi ölen grupta yüksek olsa da istatistiksel anlamlı fark saptanmadı (p=0,439). Sonuç: COVID-19 pandemisinde PNX/SCE gibi komplikasyonlar uzun süreli oksijen desteğini takiben genel yoğun bakım popülasyonundan daha sık (%9,5) ve yoğun bakım yatışının daha geç döneminde (medyan 9 gün) gözlenmektedir. Bu hastaların çoğunda bir risk faktörü olarak sigara tanımlansa da PNX oranlarındaki bu artışın hem COVID-19 pnömonisi hem de sitokin fırtınasına bağlı oluşan parankimal hasar ile ilgili olduğunu düşünüyoruz.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A. Coronavirus Disease 2019 (COVID-19): A Systematic Review of Imaging Findings in 919 Patients. AJR Am J Roentgenol 2020;215:87-93.
  • 2. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020;323:1061-9.
  • 3. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020;191:145-7.
  • 4. Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X. Analysis of 92 deceased patients with COVID-19. J Med Virol 2020;92:2511-5.
  • 5. Yao W, Wang T, Jiang B, Gao F, Wang L, Zheng H, et al. Emergency tracheal intubation in 202 patients with COVID19 in Wuhan, China: lessons learnt and international expert recommendations. Br J Anaesth 2020;125:e28-e37.
  • 6. Jacobi A, Chung M, Bernheim A, Eber C. Portable chest X-ray in coronavirus disease-19 (COVID-19): A pictorial review. Vol. 64, Clinical Imaging. Elsevier Inc; 2020. p. 35-42.
  • 7. Elhakim TS, Abdul HS, Pelaez Romero C, Rodriguez-Fuentes Y. Spontaneous pneumomediastinum, pneumothorax and subcutaneous emphysema in COVID-19 pneumonia: a rare case and literature review. BMJ Case Rep 2020;13:e239489.
  • 8. Alhakeem A, Khan MM, Al Soub H, Yousaf Z. Case Report: COVID-19- Associated Bilateral Spontaneous Pneumothorax-A Literature Review. Am J Trop Med Hyg 2020;103:1162-5.
  • 9. de Lassence A, Timsit JF, Tafflet M, Azoulay E, Jamali S, Vincent F, et al. Pneumothorax in the intensive care unit: incidence, risk factors, and outcome. Anesthesiology 2006;104:5-13.
  • 10. Lew TW, Kwek TK, Tai D, Earnest A, Loo S, Singh K, et al. Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome. JAMA 2003;290:374-80.
  • 11. Fowler RA, Lapinsky SE, Hallett D, Detsky AS, Sibbald WJ, Slutsky AS, et al. Critically ill patients with severe acute respiratory syndrome. JAMA 2003;290:367-73.
  • 12. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507-13.
  • 13. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study. Lancet Respir Med 2020;8:475- 81.
  • 14. George B, Megally M, Mrejen-Shakin K. Spontaneous pneumothorax and spontaneous pneumomediastinum in non-intubated patients in the setting of Severe Acute Respiratory Syndrome Coronavirus 2. Chest 2020;158:A1653-4.
  • 15. Muhammad AI, Boynton EJ, Naureen S. COVID-19 with bilateral pneumothoraces- case report. Respir Med Case Rep 2020;31:101254.
  • 16. Talan L, Şaşal Solmaz FG, Ercan U, Akdemir Kalkan İ, Yenigün BM, Yüksel C, et al. COVID-19 pneumonia and pneumothorax: case series. Tuberk Toraks 2020;68:437-43.
  • 17. Vahapoğlu A, Akpolat B, Çavuş Z, Genç Moralar D, Türkmen A. Spontaneous Hemopneumothorax During the Course of COVID-19 Pneumonia. Turkish J Intensive Care 2020;18:46-9.
  • 18. Lichtenstein D, Mezière G, Biderman P, Gepner A. The “lung point”: an ultrasound sign specific to pneumothorax. Intensive Care Med 2000;26:1434-40.
  • 19. Lichtenstein DA, Lascols N, Prin S, Mezière G. The “lung pulse”: an early ultrasound sign of complete atelectasis. Intensive Care Med 2003;29:2187-92.
  • 20. Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19) Intensive Care Med 2020;46:854-87.
  • 21. Özdemir S, Bilgi DÖ, Köse S, Oya G. Pneumothorax in patients with coronavirus disease 2019 pneumonia with invasive mechanical ventilation. Interact Cardiovasc Thorac Surg 2021;32:351-5.
  • 22. Guven BB, Erturk T, Kompe Ö, Ersoy A. Serious complications in COVID19 ARDS cases: pneumothorax, pneumomediastinum, subcutaneous emphysema and haemothorax. Epidemiol Infect 2021;149:e137.
  • 23. EVMS COVID-19 Management protocol An overview of the MATH+ and I-MASK+ Protocols. 2020.
  • 24. Gupta D, Hansell A, Nichols T, Duong T, Ayres JG, Strachan D. Epidemiology of pneumothorax in England. Thorax 2000;55:666-71.
  • 25. Sahn SA, Heffner JE. Spontaneous pneumothorax. N Engl J Med 2000;342:868-74.
  • 26. Comroe JH, Dripps RD, Dumke PR, Deming M. Oxygen toxicity: The effect of inhalation of high concentrations of oxygen for twenty-four hours on normal men at sea level and at a simulated altitude of 18,000 feet. J Am Med Assoc 1945;128:710-7.
  • 27. Sackner MA, Landa J, Hirsch J, Zapata A. Pulmonary effects of oxygen breathing. A 6-hour study in normal men. Ann Intern Med 1975;82:40-3.
  • 28. Carpagnano GE, Kharitonov SA, FoschinoBarbaro MP, Resta O, Gramiccioni E, Barnes PJ. Supplementary oxygen in healthy subjects and those with COPD increases oxidative stress and airway inflammation. Thorax 2004;59:1016-9.
  • 29. Mantell LL, Lee PJ. Signal transduction pathways in hyperoxia-induced lung cell death. Mol Genet Metab 2000;71:359- 70.
  • 30. Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents 2020;55:105954.
  • 31. Marini JJ, Gattinoni L. Management of COVID-19 Respiratory Distress. JAMA 2020;323:2329-30.
APA PEHLİVANLAR KÜÇÜK M, Öksüz Güngör B, KÜÇÜK A, AYÇIÇEK O, Turkyilmaz A, Öztuna F, Bulbul Y, OZLÜ T (2021). Pneumothorax and Subcutaneous Emphysema Evaluation in Patients with COVID-19 in the Intensive Care Unit. , 95 - 101. 10.4274/tybd.galenos.2021.30316
Chicago PEHLİVANLAR KÜÇÜK Mehtap,Öksüz Güngör Burcu,KÜÇÜK Ahmet Oğuzhan,AYÇIÇEK OLCAY,Turkyilmaz Atila,Öztuna Funda,Bulbul Yilmaz,OZLÜ TEVFIK Pneumothorax and Subcutaneous Emphysema Evaluation in Patients with COVID-19 in the Intensive Care Unit. (2021): 95 - 101. 10.4274/tybd.galenos.2021.30316
MLA PEHLİVANLAR KÜÇÜK Mehtap,Öksüz Güngör Burcu,KÜÇÜK Ahmet Oğuzhan,AYÇIÇEK OLCAY,Turkyilmaz Atila,Öztuna Funda,Bulbul Yilmaz,OZLÜ TEVFIK Pneumothorax and Subcutaneous Emphysema Evaluation in Patients with COVID-19 in the Intensive Care Unit. , 2021, ss.95 - 101. 10.4274/tybd.galenos.2021.30316
AMA PEHLİVANLAR KÜÇÜK M,Öksüz Güngör B,KÜÇÜK A,AYÇIÇEK O,Turkyilmaz A,Öztuna F,Bulbul Y,OZLÜ T Pneumothorax and Subcutaneous Emphysema Evaluation in Patients with COVID-19 in the Intensive Care Unit. . 2021; 95 - 101. 10.4274/tybd.galenos.2021.30316
Vancouver PEHLİVANLAR KÜÇÜK M,Öksüz Güngör B,KÜÇÜK A,AYÇIÇEK O,Turkyilmaz A,Öztuna F,Bulbul Y,OZLÜ T Pneumothorax and Subcutaneous Emphysema Evaluation in Patients with COVID-19 in the Intensive Care Unit. . 2021; 95 - 101. 10.4274/tybd.galenos.2021.30316
IEEE PEHLİVANLAR KÜÇÜK M,Öksüz Güngör B,KÜÇÜK A,AYÇIÇEK O,Turkyilmaz A,Öztuna F,Bulbul Y,OZLÜ T "Pneumothorax and Subcutaneous Emphysema Evaluation in Patients with COVID-19 in the Intensive Care Unit." , ss.95 - 101, 2021. 10.4274/tybd.galenos.2021.30316
ISNAD PEHLİVANLAR KÜÇÜK, Mehtap vd. "Pneumothorax and Subcutaneous Emphysema Evaluation in Patients with COVID-19 in the Intensive Care Unit". (2021), 95-101. https://doi.org/10.4274/tybd.galenos.2021.30316
APA PEHLİVANLAR KÜÇÜK M, Öksüz Güngör B, KÜÇÜK A, AYÇIÇEK O, Turkyilmaz A, Öztuna F, Bulbul Y, OZLÜ T (2021). Pneumothorax and Subcutaneous Emphysema Evaluation in Patients with COVID-19 in the Intensive Care Unit. Türk Yoğun Bakım Dergisi, 19(1), 95 - 101. 10.4274/tybd.galenos.2021.30316
Chicago PEHLİVANLAR KÜÇÜK Mehtap,Öksüz Güngör Burcu,KÜÇÜK Ahmet Oğuzhan,AYÇIÇEK OLCAY,Turkyilmaz Atila,Öztuna Funda,Bulbul Yilmaz,OZLÜ TEVFIK Pneumothorax and Subcutaneous Emphysema Evaluation in Patients with COVID-19 in the Intensive Care Unit. Türk Yoğun Bakım Dergisi 19, no.1 (2021): 95 - 101. 10.4274/tybd.galenos.2021.30316
MLA PEHLİVANLAR KÜÇÜK Mehtap,Öksüz Güngör Burcu,KÜÇÜK Ahmet Oğuzhan,AYÇIÇEK OLCAY,Turkyilmaz Atila,Öztuna Funda,Bulbul Yilmaz,OZLÜ TEVFIK Pneumothorax and Subcutaneous Emphysema Evaluation in Patients with COVID-19 in the Intensive Care Unit. Türk Yoğun Bakım Dergisi, vol.19, no.1, 2021, ss.95 - 101. 10.4274/tybd.galenos.2021.30316
AMA PEHLİVANLAR KÜÇÜK M,Öksüz Güngör B,KÜÇÜK A,AYÇIÇEK O,Turkyilmaz A,Öztuna F,Bulbul Y,OZLÜ T Pneumothorax and Subcutaneous Emphysema Evaluation in Patients with COVID-19 in the Intensive Care Unit. Türk Yoğun Bakım Dergisi. 2021; 19(1): 95 - 101. 10.4274/tybd.galenos.2021.30316
Vancouver PEHLİVANLAR KÜÇÜK M,Öksüz Güngör B,KÜÇÜK A,AYÇIÇEK O,Turkyilmaz A,Öztuna F,Bulbul Y,OZLÜ T Pneumothorax and Subcutaneous Emphysema Evaluation in Patients with COVID-19 in the Intensive Care Unit. Türk Yoğun Bakım Dergisi. 2021; 19(1): 95 - 101. 10.4274/tybd.galenos.2021.30316
IEEE PEHLİVANLAR KÜÇÜK M,Öksüz Güngör B,KÜÇÜK A,AYÇIÇEK O,Turkyilmaz A,Öztuna F,Bulbul Y,OZLÜ T "Pneumothorax and Subcutaneous Emphysema Evaluation in Patients with COVID-19 in the Intensive Care Unit." Türk Yoğun Bakım Dergisi, 19, ss.95 - 101, 2021. 10.4274/tybd.galenos.2021.30316
ISNAD PEHLİVANLAR KÜÇÜK, Mehtap vd. "Pneumothorax and Subcutaneous Emphysema Evaluation in Patients with COVID-19 in the Intensive Care Unit". Türk Yoğun Bakım Dergisi 19/1 (2021), 95-101. https://doi.org/10.4274/tybd.galenos.2021.30316